JP2023530271A - Apol1の阻害剤及びこれを使用する方法 - Google Patents
Apol1の阻害剤及びこれを使用する方法 Download PDFInfo
- Publication number
- JP2023530271A JP2023530271A JP2022575989A JP2022575989A JP2023530271A JP 2023530271 A JP2023530271 A JP 2023530271A JP 2022575989 A JP2022575989 A JP 2022575989A JP 2022575989 A JP2022575989 A JP 2022575989A JP 2023530271 A JP2023530271 A JP 2023530271A
- Authority
- JP
- Japan
- Prior art keywords
- groups
- branched
- optionally substituted
- hydroxy
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063038275P | 2020-06-12 | 2020-06-12 | |
| US63/038,275 | 2020-06-12 | ||
| US202063040183P | 2020-06-17 | 2020-06-17 | |
| US63/040,183 | 2020-06-17 | ||
| PCT/US2021/036954 WO2021252859A1 (en) | 2020-06-12 | 2021-06-11 | Inhibitors of apol1 and use of the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023530271A true JP2023530271A (ja) | 2023-07-14 |
| JP2023530271A5 JP2023530271A5 (cg-RX-API-DMAC7.html) | 2024-06-06 |
Family
ID=76731125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022575989A Pending JP2023530271A (ja) | 2020-06-12 | 2021-06-11 | Apol1の阻害剤及びこれを使用する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12281102B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4165022A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023530271A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116157393A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021286728A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3185604A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021252859A1 (cg-RX-API-DMAC7.html) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025503737A (ja) * | 2022-01-18 | 2025-02-04 | メイズ セラピューティクス, インコーポレイテッド | Apol1阻害剤及び使用方法 |
| JP7909027B2 (ja) | 2022-01-18 | 2026-08-20 | メイズ セラピューティクス, インコーポレイテッド | Apol1阻害剤及び使用方法 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3897833T (lt) | 2018-12-17 | 2026-04-27 | Vertex Pharmaceuticals Incorporated | Apol1 inhibitoriai ir jų panaudojimo būdai |
| EP4097083A1 (en) | 2020-01-29 | 2022-12-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
| EP4114385A1 (en) | 2020-03-06 | 2023-01-11 | Vertex Pharmaceuticals Incorporated | Methods of treating apol-1 dependent focal segmental glomerulosclerosis |
| EP4146633A4 (en) | 2020-05-07 | 2024-09-25 | Rambam Med-Tech Ltd. | COMPOSITION FOR USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH APOL1 |
| JP2023530271A (ja) | 2020-06-12 | 2023-07-14 | バーテックス ファーマシューティカルズ インコーポレイテッド | Apol1の阻害剤及びこれを使用する方法 |
| CN115867543A (zh) | 2020-06-12 | 2023-03-28 | 弗特克斯药品有限公司 | Apol1抑制剂的固体形式及其使用方法 |
| BR112023003423A2 (pt) | 2020-08-26 | 2023-03-21 | Vertex Pharma | Inibidores de apol1 e métodos de uso destes |
| US12612379B2 (en) | 2021-11-30 | 2026-04-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| WO2026078446A2 (en) * | 2024-10-08 | 2026-04-16 | Brandaris Therapeutics B.V. | 5,6-bicyclic 5-ht2ar agonists and uses thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1266763B (de) * | 1965-07-27 | 1968-04-25 | Kalle Ag | Verfahren zur Herstellung von in 3-Stellung substituierten Indol- und Indazolderivaten |
| JP2011525915A (ja) * | 2008-06-26 | 2011-09-29 | アムジエン・インコーポレーテツド | キナーゼ阻害薬としてのアルキニルアルコール類 |
| CN106008477A (zh) * | 2016-06-02 | 2016-10-12 | 苏州大学 | 3-(2-芳基-1h-吲哚-3-基)-4-羟基呋喃-2(5h)-酮及其合成方法 |
| JP7573528B2 (ja) * | 2018-12-17 | 2024-10-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | Apol1の阻害剤及びその使用方法 |
| JP7668804B2 (ja) * | 2020-01-29 | 2025-04-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | Apol1の阻害剤およびこれを使用する方法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0924209B1 (en) | 1997-12-19 | 2003-05-02 | Eli Lilly And Company | Hypoglycemic imidazoline compounds |
| GB9816263D0 (en) * | 1998-07-24 | 1998-09-23 | Merck Sharp & Dohme | Therapeutic agents |
| GB9905010D0 (en) | 1999-03-04 | 1999-04-28 | Merck Sharp & Dohme | Therapeutic agents |
| WO2001017965A2 (en) | 1999-09-07 | 2001-03-15 | Syngenta Participations Ag | Cyanopiperidines as pesticides |
| FR2801585B1 (fr) | 1999-11-25 | 2002-02-15 | Fournier Ind & Sante | Nouveaux antagonistes des recepteurs de l'ii-8 |
| GB0003397D0 (en) | 2000-02-14 | 2000-04-05 | Merck Sharp & Dohme | Therapeutic agents |
| WO2002028831A1 (en) | 2000-10-02 | 2002-04-11 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| FR2824826B1 (fr) | 2001-05-17 | 2003-11-07 | Fournier Lab Sa | Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8 |
| FR2824827B1 (fr) | 2001-05-17 | 2004-02-13 | Fournier Lab Sa | Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8 |
| KR20050044450A (ko) | 2001-11-14 | 2005-05-12 | 테바 파마슈티컬 인더스트리즈 리미티드 | 로사르탄 칼륨의 무정형 및 결정형 형태 및 이의 제조 방법 |
| WO2003104180A1 (en) | 2002-06-05 | 2003-12-18 | Natco Pharma Limited | Process for the preparation of 4-(4-fluorobenzoyl) butyric acid |
| WO2004058717A1 (en) | 2002-12-20 | 2004-07-15 | X-Ceptor Therapeutics, Inc. | Isoquinolinone derivatives and their use as therapeutic agents |
| AU2004268919A1 (en) | 2003-09-03 | 2005-03-10 | Galapagos Nv | Novel 4-piperidinecarboxamide and the use thereof for the preparation of medicaments against 5-HT2A receptor-related disorders |
| WO2005092854A1 (en) | 2004-03-03 | 2005-10-06 | Eli Lilly And Company | Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators |
| WO2007061763A2 (en) | 2005-11-22 | 2007-05-31 | Merck & Co., Inc. | Indole orexin receptor antagonists |
| PT2118074E (pt) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
| EP2178870B1 (en) | 2007-08-17 | 2018-09-19 | LG Chem, Ltd. | Indole and indazole compounds as an inhibitor of cellular necrosis |
| KR101605061B1 (ko) | 2009-05-29 | 2016-03-21 | 라퀄리아 파마 인코포레이티드 | 칼슘 또는 나트륨 채널 차단제로서의 아릴 치환된 카복사미드 유도체 |
| WO2012025155A1 (en) | 2010-08-26 | 2012-03-01 | Novartis Ag | Hydroxamate-based inhibitors of deacetylases |
| US10130632B2 (en) | 2012-11-27 | 2018-11-20 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating renal disease |
| US9850203B2 (en) | 2013-09-26 | 2017-12-26 | Pharmakea, Inc. | Autotaxin inhibitor compounds |
| ES2895490T3 (es) | 2014-03-27 | 2022-02-21 | Acad Medisch Ct | Iminoazúcares N-(5-(bifen-4-ilmetiloxi)pentil)-sustituidos como inhibidores de glucosilceramida sintasa |
| WO2016029310A1 (en) | 2014-08-27 | 2016-03-03 | The Governing Council Of The University Of Toronto | Cannabinoid type 1 receptor modulators |
| BR112017007178A2 (pt) | 2014-10-08 | 2017-12-19 | Ass Francaise Contre Les Myopathies | compostos de aminopiridina úteis como inibidores de prenilação de proteína |
| HRP20210472T1 (hr) | 2015-08-27 | 2021-05-14 | Pfizer Inc. | Biciklički kondenzirani heteroarilni ili arilni spojevi kao modulatori irak4 |
| EP3787669A4 (en) | 2018-04-30 | 2022-03-30 | The Trustees of Indiana University | COMPOUNDS FOR MODULATION OF LEVELS OF DDAH AND ADMA AND METHODS OF USE THEM TO TREAT DISEASES |
| CN118127019A (zh) | 2018-05-22 | 2024-06-04 | Ionis制药公司 | Apol1表达的调节剂 |
| US20210246121A1 (en) | 2020-02-04 | 2021-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of apol1 inhibitor and methods of using same |
| EP4114385A1 (en) | 2020-03-06 | 2023-01-11 | Vertex Pharmaceuticals Incorporated | Methods of treating apol-1 dependent focal segmental glomerulosclerosis |
| EP4146633A4 (en) | 2020-05-07 | 2024-09-25 | Rambam Med-Tech Ltd. | COMPOSITION FOR USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH APOL1 |
| CN115867543A (zh) | 2020-06-12 | 2023-03-28 | 弗特克斯药品有限公司 | Apol1抑制剂的固体形式及其使用方法 |
| US20230014907A1 (en) | 2020-06-12 | 2023-01-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
| JP2023530271A (ja) | 2020-06-12 | 2023-07-14 | バーテックス ファーマシューティカルズ インコーポレイテッド | Apol1の阻害剤及びこれを使用する方法 |
| BR112023003423A2 (pt) | 2020-08-26 | 2023-03-21 | Vertex Pharma | Inibidores de apol1 e métodos de uso destes |
| KR20240051990A (ko) | 2021-08-26 | 2024-04-22 | 버텍스 파마슈티칼스 인코포레이티드 | 스피로트리시클릭 apol1 억제제의 고형분 형태 및 이의 사용 방법 |
| US12612379B2 (en) | 2021-11-30 | 2026-04-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| AU2022401847A1 (en) | 2021-11-30 | 2024-06-06 | Vertex Pharmaceuticals Incorporated | Spirocyclic inhibitors of apol1 and methods of using same |
| EP4476228A1 (en) | 2022-02-08 | 2024-12-18 | Vertex Pharmaceuticals Incorporated | 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same |
| CN119343353A (zh) | 2022-02-08 | 2025-01-21 | 弗特克斯药品有限公司 | 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法 |
| WO2023154314A1 (en) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Spiro piperidine derivatives as inhibitors of apol1 and methods of using same |
| EP4476199A1 (en) | 2022-02-08 | 2024-12-18 | Vertex Pharmaceuticals Incorporated | 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same |
-
2021
- 2021-06-11 JP JP2022575989A patent/JP2023530271A/ja active Pending
- 2021-06-11 AU AU2021286728A patent/AU2021286728A1/en not_active Abandoned
- 2021-06-11 CA CA3185604A patent/CA3185604A1/en active Pending
- 2021-06-11 EP EP21736922.2A patent/EP4165022A1/en not_active Withdrawn
- 2021-06-11 US US17/345,268 patent/US12281102B2/en active Active
- 2021-06-11 CN CN202180056005.4A patent/CN116157393A/zh active Pending
- 2021-06-11 WO PCT/US2021/036954 patent/WO2021252859A1/en not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1266763B (de) * | 1965-07-27 | 1968-04-25 | Kalle Ag | Verfahren zur Herstellung von in 3-Stellung substituierten Indol- und Indazolderivaten |
| JP2011525915A (ja) * | 2008-06-26 | 2011-09-29 | アムジエン・インコーポレーテツド | キナーゼ阻害薬としてのアルキニルアルコール類 |
| CN106008477A (zh) * | 2016-06-02 | 2016-10-12 | 苏州大学 | 3-(2-芳基-1h-吲哚-3-基)-4-羟基呋喃-2(5h)-酮及其合成方法 |
| JP7573528B2 (ja) * | 2018-12-17 | 2024-10-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | Apol1の阻害剤及びその使用方法 |
| JP7668804B2 (ja) * | 2020-01-29 | 2025-04-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | Apol1の阻害剤およびこれを使用する方法 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025503737A (ja) * | 2022-01-18 | 2025-02-04 | メイズ セラピューティクス, インコーポレイテッド | Apol1阻害剤及び使用方法 |
| JP7909027B2 (ja) | 2022-01-18 | 2026-08-20 | メイズ セラピューティクス, インコーポレイテッド | Apol1阻害剤及び使用方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116157393A (zh) | 2023-05-23 |
| AU2021286728A1 (en) | 2023-01-19 |
| WO2021252859A1 (en) | 2021-12-16 |
| CA3185604A1 (en) | 2021-12-16 |
| US20230011118A1 (en) | 2023-01-12 |
| EP4165022A1 (en) | 2023-04-19 |
| US12281102B2 (en) | 2025-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7668804B2 (ja) | Apol1の阻害剤およびこれを使用する方法 | |
| US12281102B2 (en) | Inhibitors of APOL1 and methods of using same | |
| US20250042878A1 (en) | Inhibitors of apol1 and methods of using same | |
| JP2023529216A (ja) | Apol1の阻害剤及びその使用 | |
| KR101458007B1 (ko) | 사이클로프로판 화합물 | |
| CN102229605B (zh) | 关于hiv整合酶的n-取代的羟基嘧啶酮甲酰胺抑制剂 | |
| JP2021036004A (ja) | Retの阻害剤 | |
| JP2022511572A (ja) | Il-17調節剤としてのベンズイミダゾロン誘導体及びその類似体 | |
| AU2017305399A1 (en) | Symmetric or semi-symmetric compounds useful as immunomodulators | |
| CN104684915A (zh) | 新型双环衍生物 | |
| AU1382500A (en) | Pyrrolidine derivatives-ccr-3 receptor antagonists | |
| AU2022217353B2 (en) | Pyridopyrimidinone derivative, preparation method therefor, and use thereof | |
| KR20140040774A (ko) | 이미다조피리딘 화합물 | |
| JP2016535042A (ja) | 2−ベンジル−ベンゾイミダゾール補体因子b阻害剤およびその使用 | |
| JP2023520207A (ja) | アルファ1-アンチトリプシンのモジュレーター | |
| US6710064B2 (en) | Hydantoin compounds useful as anti-inflammatory agents | |
| AU2023254866A1 (en) | Compounds and compositions for treating conditions associated with APJ receptor activity | |
| CN114127054B (zh) | 作为用于治疗炎性气道或纤维化疾病的自分泌运动因子(atx)调节剂的n-甲基、n-(6-(甲氧基)哒嗪-3-基)胺衍生物 | |
| JP2022551156A (ja) | 疼痛に対する多様な活性を有するホモピペラジニル及びホモピペリジニルキナゾリン-4(3h)-オン誘導体 | |
| MXPA04012345A (es) | Derivados de pirimidina 2,5-substituida como antagonistas ix del receptor ccr-3. | |
| CN118724900A (zh) | 4-氨基-7-氮杂吲哚类化合物、其制备方法及应用 | |
| TW201307300A (zh) | 趨代謝性麩胺酸受體調節劑 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240529 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240529 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250526 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250529 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20251114 |